Matrixyl 3000 vs Oligopeptide-1
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7
Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.
Also: sh-Oligopeptide-1, rh-Oligopeptide-1
sh-Oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (EGF), a 53-amino-acid protein your skin uses to tell cells to divide and repair. It shows up in 'EGF serums' aimed at wrinkles, texture and post-procedure recovery. It is a cosmetic ingredient in skincare, not an FDA-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Oligopeptide-1 has stronger research evidence (Human Trials) compared to Matrixyl 3000 (Limited Research).
Detailed Comparison
| Attribute | Matrixyl 3000 | Oligopeptide-1 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Both peptides are matrikines, short collagen-derived signals the skin treats as repair instructions. Palmitoyl tripeptide-1 nudges fibroblasts to produce more collagen, elastin and fibronectin, the scaffolding that keeps skin firm. Palmitoyl tetrapeptide-7 works on the other side of the equation by tamping down release of interleukin-6, an inflammatory messenger that climbs with age and quietly accelerates matrix breakdown, which in turn is thought to limit collagen glycation damage. As with the original Matrixyl, the palmitoyl tails are there to ferry these water-loving peptides through the skin barrier. The combined claim is build more, lose less. | EGF binds the EGF receptor on keratinocytes and fibroblasts and switches on growth and repair signaling: cell division, migration, and production of matrix proteins. That is why it has been studied for wound healing, and why cosmetic brands use it to support skin renewal. Two practical problems: EGF is a fairly large protein, so getting it through intact skin is hard (which is why many studies pair it with microneedling or lasers), and it is fragile, so how much stays active in a jar at room temperature is a fair question. The same growth-promoting signal is also the source of the safety debate: EGF receptor signaling drives several cancers, so the concern is not that EGF causes cancer, but whether it could encourage abnormal cells that are already there. |
| Common Dosing | Limited community data available See research protocols | Low parts-per-million concentration in a serum Once or twice daily |
| Administration | Topical (serums, creams) | Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic |
| Typical Duration | Ongoing use for maintained effects | Studies typically ran 4 to 12 weeks |
| Best Time to Take | Morning or as directed | Evening skincare routine, or right after an in-clinic procedure |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Matrixyl 3000 has a coherent, biologically reasonable mechanism, and in vitro studies do show its components stimulating fibroblast proliferation and synthesis of collagen types I, III, IV and VII, with the tetrapeptide reducing IL-6. The catch for a careful reader is that most of the supporting clinical work, including the commonly cited 12-week trials reporting reductions in wrinkles and skin laxity, originates from or was sponsored by the manufacturer rather than independent labs, and large published placebo-controlled trials specific to this exact complex are sparse. The strongest truly independent peptide evidence in this family is still the original Pal-KTTKS Matrixyl data. So Matrixyl 3000 is best described as a sensible, well-tolerated upgrade on paper with solid mechanistic and in vitro backing, but with human efficacy that rests heavily on industry sources rather than rigorous third-party trials. It targets collagen and inflammation, not muscle, so expectations should be texture and firmness, not Botox-like smoothing. | A 2021 systematic review in the Journal of Cutaneous and Aesthetic Surgery (Miller-Kobisher and colleagues) found 49 articles on rhEGF for skin, including 23 aesthetic studies. Most reported less wrinkling, better hydration and elasticity, and the strongest data were for pigmentation after lasers and melasma. But the authors admit many trials were uncontrolled or not randomized, samples were often 8 to 40 people, and they called for proper controlled trials. Adverse effects were mild and short-lived. The review did not address cancer risk at all, which is a real gap. Several of the better-known growth-factor trials tested multi-factor mixtures, not EGF alone. On safety: there is no human evidence that cosmetic EGF causes skin cancer, and in vitro tests of growth-factor cosmetics on melanoma cells were reassuring, but long-term studies in healthy skin do not exist. Sensible caution: people with a history of skin cancer, many atypical moles, or active psoriasis should talk to a dermatologist before using it. Bottom line: plausible and widely used, modest and mostly low-quality efficacy data, and an unresolved theoretical safety question. |
Frequently Asked Questions: Matrixyl 3000 vs Oligopeptide-1
What is the difference between Matrixyl 3000 and Oligopeptide-1?
Matrixyl 3000 is a skin & hair peptide that matrixyl 3000 is sederma's follow-up to the original matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (pal-ghk) and palmitoyl tetrapeptide-7 (pal-gqpr). the idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. it is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence. Oligopeptide-1 is a skin & hair peptide that sh-oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (egf), a 53-amino-acid protein your skin uses to tell cells to divide and repair. it shows up in 'egf serums' aimed at wrinkles, texture and post-procedure recovery. it is a cosmetic ingredient in skincare, not an fda-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Matrixyl 3000 or Oligopeptide-1?
Neither is universally "better" - the choice depends on your specific goals. Matrixyl 3000 is typically used for skin & hair purposes, while Oligopeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Matrixyl 3000 and Oligopeptide-1 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Matrixyl 3000 and Oligopeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.